June 5, 2017

Imaging Mass Cytometry to Profile Tumor Immune Microenvironment

Investigators: Akil Merchant M.D.; Parkash Gill M.D.; Peter Kuhn Ph.D.; Imran Siddiqi MD Ph.D.
Innovation: developing an imaging technique to study immune cells and understand their connection to tumors
Clinical significance: gain insights into immune response for patients being treated with immuno-oncology agents
June 5, 2017

Development of a Nano-Encapsulated Small Molecule Immunotherapeutic for Colon Cancer

Investigators: Nicos Petasis Ph.D.; Stan Louie Ph.D.; Heinz-Josef Lenz M.D.
Innovation: developing non-cytotoxic small molecules that cause tumor death through suppression of inflammation
Clinical significance: provides a new treatment for colon cancer and other inflammation-related cancers
June 5, 2017

Large-scale Isolation of Cytotoxic Extracellular Vesicles from Activated Natural Killer Cells for Immunotherapy of Cancer

Investigators: Noah Malmstadt Ph.D.; Robert Seeger M.D. M.S.; Muller Fabbri M.D. Ph.D.; Ambrose Jong Ph. D.; Alan Wayne M.D.
Innovation: develop a new, automated, large-scale device for purifying NK EVs and characterize their ability to kill human ALL and NB cell lines in vitro and cell lines and patient derived xenografts
Clinical significance: new approach to the treatment of cancer that may be effective against a wide array of malignancies in children and adults
March 2, 2016

Bispecific hybrid nanoworms for immunotherapy of B-cell lymphoma

Investigators: J. Andrew MacKay, Ph.D. Peter Conti, M.D., Ph.D., Alan Epstein, M.D., Ph.D. Zibo Li, Ph.D.
Innovation: Nanoworm-delivered therapeutics that can bind to more than one target
Clinical significance: New immunotherapies tailored to non-Hodgkin’s lymphoma patients
March 2, 2014

Nanoparticle-mediated delivery targeting TAK1 as a metastatic breast cancer therapy

Investigators:Min Yu, M.D., Ph.D. Pin Wang, Ph.D., Julie Lang, M.D.
Innovation: delivering a novel nanoparticle/TAK1 inhibitor to halt metastasis
Clinical significance: a new treatment for metastatic breast cancer
March 2, 2014

Optimization of pH-sensitive peptide nanoconstructs for use in targeting the mildly acidic tumor microenvironment

Investigators: Jennica Zaro, Ph.D. Peter Conti, M.D., Ph.D.
Innovation: a method to recognize the minute differences in pH levels near tumor cells
Clinical significance: enabling more powerful cancer-killing drugs to be used without side effects